All Oncology News

The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.

Adam C. Berger, MD, FACS, discusses key messages for oncologists during Sarcoma Awareness Month.

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

Yu “Sunny” Liu, PhD, has received a grant from the NIGMS of the National Institutes of Health to study how misfolded human genome can cause disease.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

The FDA has granted priority review to asciminib for newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

The addition of BNT111 to cemiplimab has produced clinical activity in anti-PD-(L)1 relapsed/refractory unresectable stage III or IV melanoma.

IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

Current screening protocols fail to catch a number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome.

The FDA has extended the PDUFA date for the NDA seeking the approval of revumenib for patients with relapsed/refractory KMT2A-rearranged acute leukemia.

China’s NMPA has accepted an sBLA for ivonescimab in first-line, PD-L1–positive non–small cell lung cancer.

The Shield blood test has been approved by the FDA for CRC screening in adults aged 45 years and older who are at average risk for the disease.

The EMA’s CHMP has recommended toripalimab plus chemotherapy for metastatic nasopharyngeal carcinoma and advanced esophageal squamous cell carcinoma.

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab elicited favorable PFS outcomes in previously untreated chronic lymphocytic leukemia.

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth and distribution of tumors.

The EMA's CHMP has recommended zolbetuximab plus chemotherapy in select locally advanced unresectable or metastatic HER2-negative gastric or GEJ cancer.

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.